Elicera Therapeutics AB
F:8E8
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Elicera Therapeutics AB
F:8E8
|
SE |
|
Solstice Gold Corp
XTSX:SGC
|
CA |
|
F
|
Fourace Industries Group Holdings Ltd
HKEX:1455
|
CN |
|
M
|
Majestic Ideal Holdings Ltd
NASDAQ:MJID
|
HK |
|
Goliath Film and Media Holdings
OTC:GFMH
|
US |
|
MainStreetChamber Holdings Inc
OTC:MSCH
|
US |
|
S
|
Sable Exploration and Mining Ltd
JSE:SXM
|
ZA |
|
I
|
Industrial Minerals Ltd
ASX:IND
|
AU |
|
Wavefront Technology Solutions Inc
XTSX:WEE
|
CA |
Elicera Therapeutics AB
Elicera Therapeutics AB operates as clinical stage immuno-oncology company, which engages in the development of cell and gene therapies for immune-based cancer treatments. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2021-06-11. The firm is developing next-generation cell and gene therapies for immune-based treatment of cancer. The firm is developing four drug candidates, two of which are in the field of oncolytic viruses and two in the field of CAR T-cell treatments. Elicera also has a fully developed platform technology called iTANK (ImmunoTherapies Activated with Nap for efficient Killing) for further immune strengthening in treatment in the said field. Elicera has two projects in each field: ELC-100 is an oncolytic virus, also called AdVince, that is in a clinical phase I/II trial, sponsored by Uppsala University, in the treatment of neuroendocrine tumors and ELC-301 is a CAR T-cell therapy in the treatment of B-cell lymphoma, which has been granted support from the Swedish Cancer Society for the planning and implementation of a clinical phase I/II CAR T-cell study.
Elicera Therapeutics AB operates as clinical stage immuno-oncology company, which engages in the development of cell and gene therapies for immune-based cancer treatments. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2021-06-11. The firm is developing next-generation cell and gene therapies for immune-based treatment of cancer. The firm is developing four drug candidates, two of which are in the field of oncolytic viruses and two in the field of CAR T-cell treatments. Elicera also has a fully developed platform technology called iTANK (ImmunoTherapies Activated with Nap for efficient Killing) for further immune strengthening in treatment in the said field. Elicera has two projects in each field: ELC-100 is an oncolytic virus, also called AdVince, that is in a clinical phase I/II trial, sponsored by Uppsala University, in the treatment of neuroendocrine tumors and ELC-301 is a CAR T-cell therapy in the treatment of B-cell lymphoma, which has been granted support from the Swedish Cancer Society for the planning and implementation of a clinical phase I/II CAR T-cell study.
